公开(公告)号：DK3245225T3

公开(公告)日：2021-10-18

申请号：DK15878250

申请日：2015-07-13

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  LOU YI-WEI ,  LIN CHIH-WEI ,  WU CHUNG-YI ,  WU HAN-CHUNG ,  YEH SHIH-CHI ,  HSU TSUI-LING

IPC: C07K16/18 ,  A61P35/00 ,  C07K16/30 ,  C12P19/14

公开(公告)号：CA2972731A1

公开(公告)日：2016-07-28

申请号：CA2972731

申请日：2016-01-25

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  CHEUNG SARAH K C ,  CHUANG PO-KAI ,  HSU TSUI-LING

IPC: G01N33/574 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.

公开(公告)号：BRPI0822472A2

公开(公告)日：2015-06-16

申请号：BRPI0822472

申请日：2008-05-29

Applicant: ACADEMIA SINICA

Inventor： HSIEH SHIE-LIANG ,  WONG CHI-HUEY ,  HSU TSUI-LING ,  CHEN SZU-TING

IPC: G01N33/53

公开(公告)号：EP2257806A4

公开(公告)日：2011-06-15

申请号：EP08873539

申请日：2008-05-29

Applicant: ACADEMIA SINICA

Inventor： HSIEH SHIE-LIANG ,  WONG CHI-HUEY ,  HSU TSUI-LING ,  CHEN SZU-TING

IPC: G01N33/53 ,  A61K39/395 ,  C12Q1/68

CPC classification number: C07K16/2851 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2319/30 ,  G01N2333/18 ,  G01N2333/185 ,  G01N2500/02

Abstract: Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-α is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-α secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%.